Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure

Putting guidelines into practice

John McMurray, Alain Cohen-Solal, Rainer Dietz, Eric Eichhorn, Leif Erhardt, F. D Richard Hobbs, Henry Krum, Aldo Maggioni, Robert S. McKelvie, Ileana L. Pina, Jordi Soler-Soler, Karl Swedberg

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Surveys of prescribing patterns in both hospitals and primary care have usually shown delays in translating the evidence from clinical trials of pharmacological agents into clinical practice, thereby denying patients with heart failure (HF) the benefits of drug treatments proven to improve well-being and prolong life. This may be due to unfamiliarity with the evidence-base for these therapies, the clinical guidelines recommending the use of these treatments or both, as well as concerns regarding adverse events. ACE inhibitors have long been the cornerstone of therapy for systolic HF irrespective of aetiology. Recent trials have now shown that treatment with beta-blockers, aldosterone antagonists and angiotensin receptor blockers also leads to substantial improvements in outcome. In order to accelerate the safe uptake of these treatments and to ensure that all eligible patients receive the most appropriate medications, a clear and concise set of clinical recommendations has been prepared by a group of clinicians with practical expertise in the management of HF. The objective of these recommendations is to provide practical guidance for non-specialists, in order to increase the use of evidenced based therapy for HF. These practical recommendations are meant to serve as a supplement to, rather than replacement of, existing HF guidelines.

Original languageEnglish (US)
Pages (from-to)710-721
Number of pages12
JournalEuropean Journal of Heart Failure
Volume7
Issue number5
DOIs
StatePublished - Aug 2005
Externally publishedYes

Fingerprint

Mineralocorticoid Receptor Antagonists
Mineralocorticoid Receptors
Angiotensin Receptor Antagonists
Practice Guidelines
Angiotensin-Converting Enzyme Inhibitors
Heart Failure
Therapeutics
Guidelines
Systolic Heart Failure
Primary Health Care
Clinical Trials
Pharmacology
Pharmaceutical Preparations

Keywords

  • ACE inhibitors
  • Aldosterone antagonists
  • Angiotensin receptor blockers
  • Beta-blockers
  • Clinical recommendations
  • Digoxin
  • Eplerenone
  • Heart failure
  • Hydralazine
  • Isosorbide dinitrate
  • Pharmacology
  • Spironolactone
  • Treatment

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure : Putting guidelines into practice. / McMurray, John; Cohen-Solal, Alain; Dietz, Rainer; Eichhorn, Eric; Erhardt, Leif; Hobbs, F. D Richard; Krum, Henry; Maggioni, Aldo; McKelvie, Robert S.; Pina, Ileana L.; Soler-Soler, Jordi; Swedberg, Karl.

In: European Journal of Heart Failure, Vol. 7, No. 5, 08.2005, p. 710-721.

Research output: Contribution to journalArticle

McMurray, J, Cohen-Solal, A, Dietz, R, Eichhorn, E, Erhardt, L, Hobbs, FDR, Krum, H, Maggioni, A, McKelvie, RS, Pina, IL, Soler-Soler, J & Swedberg, K 2005, 'Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice', European Journal of Heart Failure, vol. 7, no. 5, pp. 710-721. https://doi.org/10.1016/j.ejheart.2005.07.002
McMurray, John ; Cohen-Solal, Alain ; Dietz, Rainer ; Eichhorn, Eric ; Erhardt, Leif ; Hobbs, F. D Richard ; Krum, Henry ; Maggioni, Aldo ; McKelvie, Robert S. ; Pina, Ileana L. ; Soler-Soler, Jordi ; Swedberg, Karl. / Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure : Putting guidelines into practice. In: European Journal of Heart Failure. 2005 ; Vol. 7, No. 5. pp. 710-721.
@article{db2587d236e04261bcf54df29f6d1a0d,
title = "Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice",
abstract = "Surveys of prescribing patterns in both hospitals and primary care have usually shown delays in translating the evidence from clinical trials of pharmacological agents into clinical practice, thereby denying patients with heart failure (HF) the benefits of drug treatments proven to improve well-being and prolong life. This may be due to unfamiliarity with the evidence-base for these therapies, the clinical guidelines recommending the use of these treatments or both, as well as concerns regarding adverse events. ACE inhibitors have long been the cornerstone of therapy for systolic HF irrespective of aetiology. Recent trials have now shown that treatment with beta-blockers, aldosterone antagonists and angiotensin receptor blockers also leads to substantial improvements in outcome. In order to accelerate the safe uptake of these treatments and to ensure that all eligible patients receive the most appropriate medications, a clear and concise set of clinical recommendations has been prepared by a group of clinicians with practical expertise in the management of HF. The objective of these recommendations is to provide practical guidance for non-specialists, in order to increase the use of evidenced based therapy for HF. These practical recommendations are meant to serve as a supplement to, rather than replacement of, existing HF guidelines.",
keywords = "ACE inhibitors, Aldosterone antagonists, Angiotensin receptor blockers, Beta-blockers, Clinical recommendations, Digoxin, Eplerenone, Heart failure, Hydralazine, Isosorbide dinitrate, Pharmacology, Spironolactone, Treatment",
author = "John McMurray and Alain Cohen-Solal and Rainer Dietz and Eric Eichhorn and Leif Erhardt and Hobbs, {F. D Richard} and Henry Krum and Aldo Maggioni and McKelvie, {Robert S.} and Pina, {Ileana L.} and Jordi Soler-Soler and Karl Swedberg",
year = "2005",
month = "8",
doi = "10.1016/j.ejheart.2005.07.002",
language = "English (US)",
volume = "7",
pages = "710--721",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure

T2 - Putting guidelines into practice

AU - McMurray, John

AU - Cohen-Solal, Alain

AU - Dietz, Rainer

AU - Eichhorn, Eric

AU - Erhardt, Leif

AU - Hobbs, F. D Richard

AU - Krum, Henry

AU - Maggioni, Aldo

AU - McKelvie, Robert S.

AU - Pina, Ileana L.

AU - Soler-Soler, Jordi

AU - Swedberg, Karl

PY - 2005/8

Y1 - 2005/8

N2 - Surveys of prescribing patterns in both hospitals and primary care have usually shown delays in translating the evidence from clinical trials of pharmacological agents into clinical practice, thereby denying patients with heart failure (HF) the benefits of drug treatments proven to improve well-being and prolong life. This may be due to unfamiliarity with the evidence-base for these therapies, the clinical guidelines recommending the use of these treatments or both, as well as concerns regarding adverse events. ACE inhibitors have long been the cornerstone of therapy for systolic HF irrespective of aetiology. Recent trials have now shown that treatment with beta-blockers, aldosterone antagonists and angiotensin receptor blockers also leads to substantial improvements in outcome. In order to accelerate the safe uptake of these treatments and to ensure that all eligible patients receive the most appropriate medications, a clear and concise set of clinical recommendations has been prepared by a group of clinicians with practical expertise in the management of HF. The objective of these recommendations is to provide practical guidance for non-specialists, in order to increase the use of evidenced based therapy for HF. These practical recommendations are meant to serve as a supplement to, rather than replacement of, existing HF guidelines.

AB - Surveys of prescribing patterns in both hospitals and primary care have usually shown delays in translating the evidence from clinical trials of pharmacological agents into clinical practice, thereby denying patients with heart failure (HF) the benefits of drug treatments proven to improve well-being and prolong life. This may be due to unfamiliarity with the evidence-base for these therapies, the clinical guidelines recommending the use of these treatments or both, as well as concerns regarding adverse events. ACE inhibitors have long been the cornerstone of therapy for systolic HF irrespective of aetiology. Recent trials have now shown that treatment with beta-blockers, aldosterone antagonists and angiotensin receptor blockers also leads to substantial improvements in outcome. In order to accelerate the safe uptake of these treatments and to ensure that all eligible patients receive the most appropriate medications, a clear and concise set of clinical recommendations has been prepared by a group of clinicians with practical expertise in the management of HF. The objective of these recommendations is to provide practical guidance for non-specialists, in order to increase the use of evidenced based therapy for HF. These practical recommendations are meant to serve as a supplement to, rather than replacement of, existing HF guidelines.

KW - ACE inhibitors

KW - Aldosterone antagonists

KW - Angiotensin receptor blockers

KW - Beta-blockers

KW - Clinical recommendations

KW - Digoxin

KW - Eplerenone

KW - Heart failure

KW - Hydralazine

KW - Isosorbide dinitrate

KW - Pharmacology

KW - Spironolactone

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=23744514591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744514591&partnerID=8YFLogxK

U2 - 10.1016/j.ejheart.2005.07.002

DO - 10.1016/j.ejheart.2005.07.002

M3 - Article

VL - 7

SP - 710

EP - 721

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 5

ER -